RVNC News and Press, Revance Therapeutics Inc. From 09/10/21

- ePoster presentation highlights findings from a new post-hoc analysis evaluating efficacy and safety of the RHA® Collection - - Supports Revance’s commitment to ensuring safety and efficacy of aesthetic product portfolio among diverse patient populations - ...

- Post-hoc analysis demonstrates sustained improvement of static glabellar lines with repeated treatment of DaxibotulinumtoxinA for Injection - Results suggest that the extended duration of therapeutic benefit with DaxibotulinumtoxinA for Injection can produce dermal remodelin...

Despite the recent selloff, shares of Revance Therapeutics are up 65% since I gave a very bullish recommendation 2 years ago. In that time, we have have seen an equity raise, acquisition of sales rights for RHA fillers from Teoxane, a convertible note offering and of course the COVID-...

Revance Therapeutics, Inc. (RVNC) Q2 2021 Earnings Conference Call August 05, 2021, 04:30 PM ET Company Participants Jessica Serra - Head, IR and ESG Mark Foley - President and CEO Toby Schilke - CFO Dr. Abhay Joshi - COO and President, R&D and Product Operations Dustin Sjuts - Chief Comm...

Revance Therapeutics (NASDAQ:RVNC): Q2 GAAP EPS of -$1.07 beats by $0.06. Revenue of $18.8M (+6166.7% Y/Y) beats by $3.32M. Press Release For further details see: Revance Therapeutics EPS beats by $0.06, beats on revenue

- Q2 revenue for the RHA® Collection of dermal fillers of $17.0 million - Aesthetic accounts increased to over 2,000 from over 1,500 in the prior quarter - Fintech payment processing volume run-rate increased to over $500 million in Q2 - U.S. Food and Drug...

Conference Call Scheduled for Thursday, August 5, 2021, at 4:30 p.m. ET. Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the company will release second quarter 2021 financial ...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, today announced that the FDA plans to initiate its pre-approval inspection of the company’s manufacturing facility for DaxibotulinumtoxinA for Injection b...

The "Tesla Test" looks for the rare combination of forensic scores that preceded a 40% drop in TSLA stock in a prior ad-hoc study forecasting many other stock declines since. This ongoing test of 22 adverse fundamental forensic and value ratios across four accounting algorithms resume...

Revance Therapeutics, Inc. (RVNC) Q1 2021 Results Conference Call May 10, 2021 04:30 PM ET Company Participants Jessica Serra - Head, IR and ESG Mark Foley - President and CEO Toby Schilke - CFO Dr. Abhay Joshi - COO and President, R&D and Product Operations Dustin Sjuts - Chief Commercia...